CD244 represents a new therapeutic target in head and neck squamous cell carcinomaLaura Agresta, Edith M. Janssen, Maria Lehn et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 54
PD1 blockade enhances K<sup>+</sup> channel activity, Ca<sup>2+</sup> signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancerHannah S. Newton, Laura Conforti, Edith M. Janssen et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 33
Immune Checkpoint Inhibitors Regulate K+ Channel Activity in Cytotoxic T Lymphocytes of Head and Neck Cancer PatientsVaibhavkumar S. Gawali, Laura Conforti, Ameet A. Chimote et al.|Frontiers in Pharmacology|2021Cited by 14
Gene expression signature after one dose of neoadjuvant pembrolizumab associated with tumor response in head and neck squamous cell carcinoma (HNSCC).Eejung Kim, Trisha M. Wise‐Draper, Sarah Palackdharry et al.|Journal of Clinical Oncology|2018Cited by 4
Neoadjuvant Pembrolizumab is Active in Surgically Resected Head and Neck CancerSarah Palackdharry, Trisha M. Wise‐Draper, Maura L. Gillison et al.|International Journal of Radiation Oncology*Biology*Physics|2018Cited by 1